z-logo
Premium
Amantadine inhibits RANTES production by influenzavirus‐infected human bronchial epithelial cells
Author(s) -
Asai Yasukiyo,
Hashimoto Shu,
Kujime Kousei,
Gon Yasuhiro,
Mizumura Kenji,
Shimizu Kazufumi,
Horie Takashi
Publication year - 2001
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0703870
Subject(s) - amantadine , virology , microbiology and biotechnology , biology , immunology , chemistry
Amantadine can prevent and decrease airway inflammation by inhibiting influenza virus (IV) replication; however, the effect of amantadine on RANTES production by human bronchial epithelial cells (BEC) has not been determined. In the present study, we examined the effect of amantadine on RANTES production and also analysed p38 mitogen‐activated protein (MAP) kinase and c‐Jun‐NH 2 ‐terminal kinase (JNK) activation to clarify the mechanism in the effect of amantadine on RANTES production, since we have previously shown that p38 MAP kinase and JNK regulate RANTES production by IV‐infected BEC. BEC that had been preincubated with amantadine were infected with IV and then p38 MAP kinase and JNK activation in the cells and RANTES concentrations in the culture supernatants were determined. Amantadine‐induced inhibition of virus replication resulted in a decrease in p38 MAP kinase and JNK activity and decreased expression of RANTES in IV‐infected cells. Amantadine did not inhibit p38 MAP kinase and JNK activation induced by tumour necrosis factor‐α (TNF‐α) as a non‐viral stimulus. These results indicate that amantadine inhibits IV infection‐induced RANTES production by human BEC and that the inhibition by amantadine of RANTES production might result from an indirect inhibitory effect of amantadine on p38 MAP kinase and JNK activation via the inhibition of virus replication, and we emphasize that amantadine may produce a beneficial effect on controlling bronchial asthma exacerbation caused by IV infection.British Journal of Pharmacology (2001) 132 , 918–924; doi: 10.1038/sj.bjp.0703870

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here